Biotech Briefs
REGULATIONS
Danvers, MA–based Abiomed has sought approval from the U.S. Food and Drug Administration to market its AbioCor artificial heart under a humanitarian-device exemption. Such an exemption would allow doctors to implant the heart, which has been tested on just 14 people so far, in not more that 4,000 patients suffering from end-stage heart failure.
MILESTONE
The European Commission has given the green light for farmers throughout the European Union to buy and plant 17 varieties of genetically modified corn – the first time biotech crops have received such EU-wide authorization. All food made with the corn varieties, which St. Louis agricultural-products company Monsanto engineered to resist a pest called the corn borer, will be labeled as genetically modified.
IPO
Seattle’s Corus Pharma has filed preliminary papers with the U.S. Securities and Exchange Commission for an initial public offering. Backed in part by Cascade Investment, Bill Gates’s private fund, Corus is testing inhaled treatments for asthma and cystic fibrosis in humans.
ACQUISITION
Palo Alto, CA’s Agilent Technologies announced an agreement to acquire software firm Silicon Genetics of Redwood City, CA. The acquisition reflects an effort by Agilent – a leading maker of life-sciences and chemical-research equipment – to strengthen its position in bioinformatics.
ADVANCE
Researchers at King’s College London have created human embryonic stem cells that carry a mutation that causes cystic fibrosis. The cells could offer new opportunities for scientists to study the devastating genetic disorder and develop new treatments for it.
ETHICS
As genetics researchers continue to home in on genes that affect behavior and contribute to neurological conditions such as schizophrenia and autism, Stanford University is launching a center to study the ethical consequences of such research. One project planned for the new Center for Integration of Research on Genetics and Ethics: a Web-based ethics consultation service for geneticists.
Keep Reading
Most Popular
Large language models can do jaw-dropping things. But nobody knows exactly why.
And that's a problem. Figuring it out is one of the biggest scientific puzzles of our time and a crucial step towards controlling more powerful future models.
How scientists traced a mysterious covid case back to six toilets
When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.
The problem with plug-in hybrids? Their drivers.
Plug-in hybrids are often sold as a transition to EVs, but new data from Europe shows we’re still underestimating the emissions they produce.
Google DeepMind’s new generative model makes Super Mario–like games from scratch
Genie learns how to control games by watching hours and hours of video. It could help train next-gen robots too.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.